Tags : Evarsana

PharmaShots Weekly Snapshot (January 20-24, 2020)

1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, First Therapy, Epithelioid Sarcoma 2. Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US Published: Jan 23, 2020 | Tags: Evarsana, Signs, […]Read More

Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti

Shots: Evoke to receive $5M revolving credit facility following FDA approval of Gimoti while Eversana will utilize its outsourced services to commercialize and distribute Gimoti in the US Evoke will remain responsible for legal, regulatory, and manufacturing activities and retain 80% of the profit and record sales for Gimoti to Eversana’s third-party logistics division. Evarsana […]Read More